135 results found
Fenton NK, Khan SA, Marcinkowski H, et al., 2012, A SPECIALIST CIRRHOSIS CLINIC IMPROVES SCREENING, PATIENT SATISFACTION AND ATTENDANCE OF PATIENTS WITH ADVANCED LIVER DISEASE, GUT, Vol: 61, Pages: A287-A287, ISSN: 0017-5749
Pinato DJ, Stebbing J, Ishizuka M, et al., 2012, A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI), Publisher: Elsevier, Pages: 1013-1020, ISSN: 1600-0641
Background & AimsOutcome prediction is uniquely different in hepatocellular carcinoma (HCC) as the progressive functional impairment of the liver impacts patient survival independently of tumour stage. As chronic inflammation is associated with the pathogenesis of HCC, we explored the prognostic impact of a panel of inflammatory based scores, including the modified Glasgow Prognostic Score (mGPS), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), in independent cohorts.MethodsInflammatory markers, Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program (CLIP) scores were studied in a training set of 112 patients with predominantly unresectable HCC (75%). Independent predictors of survival identified in multivariate analysis were validated in an independent cohort of 466 patients with an overall lower tumour burden (BCLC-A, 56%).ResultsIn both training and validation sets, mGPS and CLIP scores emerged as independent predictors of overall survival. The predictive accuracy of the combined mGPS and CLIP score (c score 0.7, 95% CI 0.6–0.8) appeared superior to that of the CLIP score alone (c score 0.6, 95% CI 0.5–0.7).ConclusionsSystemic inflammation as measured by the mGPS, independently predicts overall survival in HCC. We have validated a novel, easy to use inflammatory score that can be used to stratify individuals. These data enable formulation of a new prognostic system, the inflammation based index in HCC (IBI). Further validation of the IBI considering treatment allocation and survival is warranted in an independent patient cohort.
Patel M, Shariff MIF, Ladep NG, et al., 2012, Hepatocellular carcinoma: diagnostics and screening, JOURNAL OF EVALUATION IN CLINICAL PRACTICE, Vol: 18, Pages: 335-342, ISSN: 1356-1294
Khan SA, Emadossadaty S, Ladep NG, et al., 2012, Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?, JOURNAL OF HEPATOLOGY, Vol: 56, Pages: 848-854, ISSN: 0168-8278
Shariff MIF, Keun HC, Beckonert O, et al., 2012, PLASMA METABOLITE PROFILING IN A RAT MODEL OF HEPATOCELLULAR CARCINOMA AND THE EFFECTS OF SELECTIVE GUT DECONTAMINATION, 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER SCIENCE BV, Pages: S125-S126, ISSN: 0168-8278
Shariff MIF, Lewis MR, Want EJ, et al., 2012, BLOOD LIPIDOMIC PROFILING OF HEPATOCELLULAR CARCINOMA IN HUMAN AND ANIMAL STUDIES IDENTIFIES LYSOPHOSPHATIDYLCHOLINE (24,0,0) AS A DISCRIMINATORY BIOMARKER, 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER SCIENCE BV, Pages: S294-S294, ISSN: 0168-8278
Ladep NG, Khan SA, Thillainayagam AV, et al., 2012, MORTALITY RATES OF PRIMARY LIVER CANCER ARE CONTINUING TO INCREASE GLOBALLY, 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER SCIENCE BV, Pages: S287-S287, ISSN: 0168-8278
Wadsworth CA, Horneffer-van der Sluis VM, Zabron A, et al., 2012, INCREASED LEVELS OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) IN THE PLASMA OF CHOLANGIOCARCINOMA PATIENTS, 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER SCIENCE BV, Pages: S130-S130, ISSN: 0168-8278
Pinato DJ, Stebbing J, Ishizuka M, et al., 2012, A novel and validated prognostic index in hepatocellular carcinoma: the Inflammation Based Index (IBI)., EASL International Liver Meeting
Khan SA, Toledano MB, Ahmed M, et al., 2012, Liver Cancer: The view from the United Kingdom, Clinical Dilemmas in Primary Liver Cancer, Editors: Williams, Taylor-Robinson, Publisher: Wiley, ISBN: 9780470657973
Incidence and mortality rates for both chronic liver disease (CLD) and liver cancer are increasing steadily in the United Kingdom. This is related to an increase in known risk factors. Alcohol consumption and non-alcoholic fatty liverdisease (NAFLD) have increased over recent decades. Chronic viral hepatitis has also increased because of increased immigration from hepatitis C virus(HBV)-endemic regions of the world and because of patients infected with hepatitis C virus (HCV) 20–30 years ago now presenting with clinical disease. There is currently a need for organised, formal hepatocellular carcinoma (HCC) surveillance, while increased incidence presents challenges for allocation of resources for treatment of HCC. Political help will be required, as the increasing health burden of liver disease raises public health issues in relation to health funding and addressing the underlying causes.
The incidence of chronic liver disease and, consequently, liver cancer is increasing in the United Kingdom at an alarming rate, and various reasons have been postulated. Alcohol consumption has increased over recent decades. The prevalence of non-alcoholic fatty liver disease has risen alongside obesity and diabetes. Chronic viral hepatitis infection are also on the rise due to increased immigration from HBV-endemic regions of the world and due to the cohort effect of previously infected HCV patients in the United Kingdom now presenting with liver disease. As well as being causes of cirrhosis, the background upon which most hepatocellular cancers (HCCs) arise, there is increasing evidence that each of these factors are independent risk factors for HCC carcinogenesis. The rising burden of chronic liver disease in the United Kingdom creates challenges for the surveillance and treatment of HCC and raises important public health issues in relation to health funding and tackling the underlying causes. © 2012 John Wiley & Sons, Ltd.
Dixon PH, Wadsworth CA, Chambers J, et al., 2011, DOES COMMON GENETIC VARIATION AROUND THE PREGNANE-X RECEPTOR INFLUENCE SUSCEPTIBILITY TO INTRAHEPATIC CHOLESTASIS OF PREGNANCY?, 62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Publisher: WILEY-BLACKWELL, Pages: 924A-924A, ISSN: 0270-9139
Zabron AA, Horneffer-van der Sluis VM, Wadsworth CA, et al., 2011, Elevated Levels of Neutrophil Gelatinase-Associated Lipocalin in Bile From Patients With Malignant Pancreatobiliary Disease, AMERICAN JOURNAL OF GASTROENTEROLOGY, Vol: 106, Pages: 1711-1717, ISSN: 0002-9270
AbdAlla MSH, Taylor-Robinson SD, Sharif AW, et al., 2011, Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma, HPB, Vol: 13, Pages: 385-390, ISSN: 1365-182X
Shariff MIF, Gomaa AI, Cox IJ, et al., 2011, Urinary Metabolic Biomarkers of Hepatocellular Carcinoma in an Egyptian Population: A Validation Study, JOURNAL OF PROTEOME RESEARCH, Vol: 10, Pages: 1828-1836, ISSN: 1535-3893
Wadsworth CA, Dixon PH, Zabron AA, et al., 2011, GENETIC VARIATION IN NATURAL KILLER CELL RECEPTOR PROTEIN G2D DOES NOT MODIFY SUSCEPTIBILITY TO SPORADIC CHOLANGIOCARCINOMA, Annual Meeting on British-Society-of-Gasenterology, Publisher: B M J PUBLISHING GROUP, ISSN: 0017-5749
Wadsworth CA, Dixon PH, Zabron AA, et al., 2011, COMMON GENETIC VARIATION IN NATURAL KILLER CELL RECEPTOR PROTEIN G2D DOES NOT MODIFY SUSCEPTIBILITY TO SPORADIC CHOLANGIOCARCINOMA, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER SCIENCE BV, Pages: S108-S109, ISSN: 0168-8278
Wadsworth CA, Dixon PH, Zabron AA, et al., 2011, GENETIC VARIATION IN BILIARY TRANSPORTERS AS A SUSCEPTIBILITY FACTOR FOR CHOLANGIOCARCINOMA, 46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Publisher: ELSEVIER SCIENCE BV, Pages: S109-S109, ISSN: 0168-8278
Wadsworth CA, Dixon PH, Wong JH, et al., 2011, Genetic Factors in the Pathogenesis of Cholangiocarcinoma, DIGESTIVE DISEASES, Vol: 29, Pages: 93-97, ISSN: 0257-2753
Asgheddi M, Abdullah M, ODonoghue M, et al., 2010, PREVALENCE OF VIRAL HEPATITIS IN PATIENTS UNDERGOING ANTI-TUBERCULOSIS THERAPY IN WEST LONDON, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: WILEY-BLACKWELL, Pages: 685A-686A, ISSN: 0270-9139
Dixon PH, Wadsworth CA, Chambers J, et al., 2010, THE ROLE OF COMMON GENETIC VARIATION AROUND SIX CANDIDATE LOCI FOR SUSCEPTIBILITY TO INTRAHEPATIC CHOLESTASIS OF PREGNANCY, 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: WILEY-BLACKWELL, Pages: 479A-479A, ISSN: 0270-9139
Sharif AW, Williams HRT, Lampejo T, et al., 2010, Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy, HPB, Vol: 12, Pages: 396-402, ISSN: 1365-182X
Zabron AA, Horneffer-Van der Sluis VM, Geirula M, et al., 2010, PROTEOMIC ANALYSIS OF BILE IN BENIGN AND MALIGNANT PANCREATOBILIARY DISEASE, Annual General Meeting of the British-Society-of-Gastroenterology, Publisher: B M J PUBLISHING GROUP, Pages: A82-A83, ISSN: 0017-5749
Mullish BH, Khan SA, 2010, Ascites, Student BMJ, Vol: 18
Shariff MIF, Ladep NG, Cox IJ, et al., 2010, Characterization of Urinary Biomarkers of Hepatocellular Carcinoma Using Magnetic Resonance Spectroscopy in a Nigerian Population, JOURNAL OF PROTEOME RESEARCH, Vol: 9, Pages: 1096-1103, ISSN: 1535-3893
Khan SA, Emadossadaty S, Taylor-Robinson SD, et al., 2010, MISCLASSIFICATION OF HILAR (KLATSKIN) CHOLANGIOCARCINOMAS: AN INVESTIGATION OF CODING PRACTICE IN THE UK, 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Publisher: ELSEVIER SCIENCE BV, Pages: S221-S221, ISSN: 0168-8278
Tanwar S, Khan SA, Grover VPB, et al., 2009, Liver transplantation for hepatocellular carcinoma, WORLD JOURNAL OF GASTROENTEROLOGY, Vol: 15, Pages: 5511-5516, ISSN: 1007-9327
Wadsworth CA, Young IR, Rea M, et al., 2009, A CATHETER-MOUNTED MAGNETIC RESONANCE DETECTOR COIL FOR BILIARY IMAGING: FIRST EX VIVO HUMAN HEPATOBILIARY IMAGES, 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: JOHN WILEY & SONS INC, Pages: 740A-741A, ISSN: 0270-9139
Adenugba A, Khan SA, Taylor-Robinson SD, et al., 2009, Polychlorinated biphenyls in bile of patients with biliary tract cancer, CHEMOSPHERE, Vol: 76, Pages: 841-846, ISSN: 0045-6535
Shariff MIF, Cox IJ, Gomaa AI, et al., 2009, Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics., Expert Rev Gastroenterol Hepatol, Vol: 3, Pages: 353-367
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide and, owing to changes in the prevalence of the two major risk factors, hepatitis B virus and hepatitis C virus, its overall incidence remains alarmingly high in the developing world and is steadily rising across most of the developed world. Early diagnosis remains the key to effective treatment and there have been recent advances in both the diagnosis and therapy of HCC, which have made important impacts on the disease. This review outlines the epidemiological trends, risk factors, diagnostic developments and novel therapeutics for HCC, both in the developing and developed world.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.